Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharp and Dohme reports long-term efficacy data for Gardasil

Merck Sharp and Dohme reports long-term efficacy data for Gardasil

12th October 2017

Merck Sharp and Dohme has announced the findings of a long-term study that demonstrates the benefits offered by its human papillomavirus (HPV) vaccine Gardasil.

Results from a final analysis of the pivotal phase III efficacy, immunogenicity and safety clinical trial for Gardasil 9 showed that the vaccine was able to deliver sustained efficacy for up to six years in the per-protocol population.

This version of Gardasil is indicated for use in the prevention of cervical, vulvar, vaginal and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58, as well as genital warts and anal cancer.

A total of 14,215 female patients aged 16 to 26 years were enrolled in the study, with the results demonstrating that the vaccine can deliver tangible benefits that can be sustained over the long term.

Dr Elmar Joura, associate professor of gynaecology and obstetrics at the Medical University of Vienna, said: "Despite the progress we've made with HPV vaccination over the past 11 years, HPV-related cancers and diseases are still a significant public health issue, and continued efforts are needed to increase uptake of the vaccine."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.